HOME Research Insight Key Players in the Non-invasive Prenatal Testing (NIPT) Market Pursue Partnerships, Agreements, and Collaborations as their Key Growth Strategy.



Key Players in the Non-invasive Prenatal Testing (NIPT) Market Pursue Partnerships, Agreements, and Collaborations as their Key Growth Strategy.


Prominent players in the NIPT market include GE Healthcare (U.S.), Koninklijke Philips N.V. (Netherlands), Illumina, Inc. (U.S.), Thermo Fisher Scientific, Inc. (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Pacific Biosciences of California, Inc. (U.S.), PerkinElmer, Inc. (U.S.), QIAGEN N.V. (Germany), Agilent Technologies, Inc. (U.S.), and Beijing Genomics Institute (China).

Agreements, Collaborations, and Partnerships accounted for largest share of the strategies adopted by the key players in the NIPT market.

GE Healthcare (U.S.) is one of the leading players in the NIPT market. The company has a broad product portfolio for the ultrasound devices. Besides this, it has a strong geographical presence across 180 countries and a wide customer base in the emerging economies. The company focuses on new product launches, by developing technologically advanced ultrasound products, and on agreements, partnerships, and collaborations as its key business strategies to ensure growth in the global NIPT market. In line with this strategy, the company launched the Voluson E10 ultrasound system. This system is specifically designed for OB/GYN applications. Furthermore, the company launched the Vscan Access portable ultrasound system. The company’s leading position in this market can be attributed to its comprehensive product portfolio in the field of NIPT, strong global presence, strong R&D investments, and its diverse network of scientists.

Illumina, Inc. (U.S.) held a leadership position in the NIPT market, owing to its wide product portfolio including sequencing, genotyping, gene expression, and molecular diagnostics. The company led the market with its flagship sequencing platforms: MiniSeq Sequencing, HiSeq Series (HiSeq 2500 and HiSeq 3000/4000), MiSeq Series, NextSeq 500, and HiSeq X Five and HiSeq X Ten. It also provides reagents such as NeoPrep Library Prep System, TruSeq library preparation kits, and other sequencing reagents. The company has a strong global presence. Illumina focuses on strengthening its position by entering into numerous agreements and partnerships with other small players in the market as well as by continuously launching new products in the market.

Companies are focusing on adopting organic and inorganic growth strategies such as partnerships, agreements, collaborations, product launches, product enhancements, acquisitions, and expansions. These strategies help market players to strengthen their product offerings, cater to the unmet needs of customers, increase their profitability, and expand their presence in the global market.

The overall growth strategies mapped from 2014 to 2017 include partnerships, agreements, collaborations, product launches, acquisitions, and expansions. Agreements, collaborations, & partnerships were the key strategies adopted by industry players to achieve growth in the market. These strategies were adopted by Pacific Biosciences of California, Inc. (U.S.), Illumina, Inc. (U.S.), GE Healthcare (U.S.), Thermo Fisher Scientific, Inc. (U.S.), PerkinElmer, Inc. (U.S.), Agilent Technologies, Inc. (U.S.), and Beijing Genomics Institute (China).

Related Reports:

Non Invasive Prenatal Testing (NIPT) Market by Instruments (Ultrasound, NGS, PCR, Microarray), Consumables, Method (FCMB, cf-DNA), Application (Trisomy, Microdeletion, Genetics, Rh factor) & End User (Hospital, Diagnostic Labs) - Global Forecast to 2021

Contact:
Mr. Rohan
MarketsandMarkets™
701 Pike Street,
Suite 2175, Seattle,
WA 98101, United States
1-888-600-6441
Email: sales@marketsandmarkets.com

Connect Us

Follow us on LinkedIn  Follow us on Facebook   Follow us on Twitter 
Live Chat Support


US : 1-888-600-6441

Search reports